论文部分内容阅读
本文应用瑞典制造的Phadebas β_2-micro test对112例消化系统良性及恶性疾病甩RIA法测定血清β_2微球蛋白的结果,包括28例慢性肝炎、16例失代偿期肝硬化(11例为肝炎后肝硬化)、12例食管癌、37侧进展性胃癌、3例结肠癌、10例原发性肝癌,以及胰腺癌和胆囊癌各3例。由试验药盒提供的183例正常人β_2m正常值<3.0μg/ml;慢性肝炎患者均值为2.65±2.89μg/ml,与正常对照组比较无显著意义(P>0.05);失代偿期肝硬化患者均值为4.94±3.64μg/ml;而食管癌、胃癌、结直肠癌、原发性肝癌、胰腺癌和胆囊癌患者的β_2m均值分别为3.19±2.66μg/ml,2.30±1.48μg/m1、4.25±1.92μg/ml、3.41±1.37pg/ml、4.75±2.20μg/ml和2.67±1.39μg/ml。故在食管癌、结直肠癌、原发性肝癌、胰腺癌及肝硬化患者测定p2m水平有一定价值。上述结果提示在某些恶性肿瘤及失代偿期肝硬化患者中,血清β_2m水平升高可能是由于肿瘤细胞的合成增加,或坏死的肝细胞过多释放所致。因此,推测此乃肝硬化、肝癌及某些恶性肿瘤患者血清中β_2m升高的原因。
In this paper, the results of serum _22-microglobulin in 112 patients with benign and malignant diseases of the digestive system were measured by the Swedish-made Phadebas β 2 -micro test, including 28 cases of chronic hepatitis and 16 cases of decompensated cirrhosis (11 cases of hepatitis). Post-cirrhosis), 12 cases of esophageal cancer, 37 cases of advanced gastric cancer, 3 cases of colon cancer, 10 cases of primary liver cancer, and 3 cases of pancreatic and gallbladder cancer. The normal value of β 2 m in the 183 normal subjects provided by the test kit was <3.0 μg/ml; the mean value of patients with chronic hepatitis was 2.65±2.89 μg/ml, which was not significantly different from the normal control group (P>0.05); decompensated liver The mean value of β_2m in patients with cirrhosis was 4.94±3.64 μg/ml; the mean values of β_2m in patients with esophageal cancer, gastric cancer, colorectal cancer, primary liver cancer, pancreatic cancer, and gallbladder cancer were 3.19±2.66 μg/ml, 2.30±1.48 μg/m1, respectively. 4.25±1.92 μg/ml, 3.41±1.37 pg/ml, 4.75±2.20 μg/ml, and 2.67±1.39 μg/ml. Therefore, p2m levels in esophageal cancer, colorectal cancer, primary liver cancer, pancreatic cancer, and cirrhosis have some value. The above results suggest that in some malignant tumors and decompensated liver cirrhosis patients, elevated serum β 2 m levels may be due to increased synthesis of tumor cells, or excessive release of necrotic hepatocytes. Therefore, it is speculated that this is the reason for the increase of serum β 2 m in patients with liver cirrhosis, liver cancer, and certain malignant tumors.